NewsBenzingaBridgeBio Pharma Receives FDA Acceptance For Filing Its New Drug Application With Priority Review For Oral Infigratinib To Treat Achondroplasia BridgeBio Pharma Receives FDA Acceptance For Filing Its New Drug Application With Priority Review For Oral Infigratinib To Treat Achondroplasia Benzinga 2026.10.06 11:32 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Equal-Weight on PENN Entertainment, Lowers Price Target to $22 HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target Alphabet Stock Rises: What's Going On? $1000 Invested In Agilent Technologies 10 Years Ago Would Be Worth This Much Today Wells Fargo Maintains Equal-Weight on MGM Resorts International, Lowers Price Target to $29 Why Is Applied Digital Stock Surging on Monday?
